On Tuesday, Shares of A Schulman Inc (NASDAQ:SHLM), gained 1.16% to $35.62.
A. Schulman, approved the quarterly cash dividend of $15.00 per share on the 125,000 shares of the Company’s convertible special stock, payable on November 2, 2015 to shareholders of record on October 15, 2015.
Separately, A. Schulman’s board of directors is predictable to take action with respect to the Company’s common stock regular quarterly cash dividend during the next full board meeting, as per normal course, on or about October 15, 2015.
A. Schulman, Inc. supplies plastic compounds and resins for use in packaging, mobility, building and construction, electronics and electrical, agriculture, personal care and hygiene, custom services, sports, home, and leisure markets.
Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), declined -8.81% to $14.49, during its last trading session.
Bellicum Pharmaceuticals, declared that Tom Farrell, President and CEO, is planned to present a business overview and update at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 2:45 p.m. EDT in New York.
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.
At the end of Tuesday’s trade, Shares of Caladrius Biosciences Inc (NASDAQ:CLBS), lost -4.86% to $1.37.
Caladrius Biosciences, declares that the Company’s administration will present at multiple conferences in October.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes.
Finally, Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), ended its last trade with 8.21% gain, and closed at $0.460.
Oncolytics Biotech Inc., declared that enrollment has been accomplished in a randomized Phase II study of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston, Ontario .
“Prostate cancer remains a leading cause of cancer-related death in men,” said Dr. Brad Thompson , President and CEO of Oncolytics. “As a result, it is important that we continue to conduct studies with late-stage patients to assist improve outcomes for this group.”
The study is an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN® given in combination with docetaxel as compared to docetaxel alone. About 40 response evaluable patients were enrolled in each arm.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
